Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2016 Jan 29;25(7):827–835. doi: 10.1002/pds.3970

Figure 2.

Figure 2

Multivariable adjusted prevalence ratios for discordance between the presence of lipid-lowering medications in REGARDS data and Medicare claims.*

Note: Models include adjustment for age, sex, race, education, income, cognitive impairment, depressive symptoms, year of enrollment and State buy-in entitlement.

CATI: computer-assisted telephone interview; CI: confidence interval; LLM: lipid-lowering medication; PR: prevalence ratio; REGARDS: REasons for Geographic And Racial Differences in Stroke; US$: US dollars.

* Presence of LLMs in Medicare claims was ascertained within 120 days prior the in-home study visit for comparison with the REGARDS medication inventory, and within 120 days prior the CATI for comparison with REGARDS self-report.

† Compared with 2007.

‡ A State buy-in entitlement identifies Medicare beneficiaries with low socioeconomic resources who receive supplementary medical insurance from their state of residence to reduce the costs they are responsible for paying.